<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01308047</url>
  </required_header>
  <id_info>
    <org_study_id>CRIST016</org_study_id>
    <nct_id>NCT01308047</nct_id>
  </id_info>
  <brief_title>Comparing Heavy Levobupivacaine With Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine.</brief_title>
  <official_title>Comparative Study of Non-inferiority Between Heavy Levobupivacaine With Enantiomeric Excess of 50% (Bupivacaine S75: R25) and Heavy Racemic Bupivacaine (Bupivacaine S50: R50) in Spinal Anesthesia for Orthopedic Procedures in the Lower Limbs.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cristália Produtos Químicos Farmacêuticos Ltda.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Irmandade da Santa Casa de Misericordia de Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Serviço Social da Indústria do Papel, Papelão e Cortiça do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cristália Produtos Químicos Farmacêuticos Ltda.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the non-inferiority between Heavy Levobupivacaine
      with Enantiomeric Excess of 50% and Heavy Racemic Bupivacaine During Spinal Anesthesia for
      Orthopedic Procedures in the Lower Limbs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Heavy Levobupivacaine with Enantiomeric Excess of 50% was developed to be a safe local
      anesthetic replacing the Heavy Racemic Bupivacaine.

      This study will evaluate the non-inferiority regarding efficacy and safety of spinal
      anesthesia in orthopedic procedures.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    The Sponsor has no interest in continuing the study.
  </why_stopped>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time of latency for sensory block at T10 dermatome.</measure>
    <time_frame>+/- 40 min after injection</time_frame>
    <description>Evaluate the sensory block at T10 after the anesthetic injection through sensory stimulation by needle.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory block duration</measure>
    <time_frame>+/- 3 hours</time_frame>
    <description>Verifying the duration of anesthesia from after puncture till the presence of positive sensitivity by needle stimulation region of the foot.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor Block Evaluation</measure>
    <time_frame>+/- 30 min</time_frame>
    <description>Motor block evaluation by Bromage Scale every five minutes after puncture till 20 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum cranial dispersion verifying the largest metamer achieved.</measure>
    <time_frame>+/- 45 min</time_frame>
    <description>Evaluated by needle stimulation every 2 minutes from the removal of post-puncture needle until the maximum extension time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the cardiocirculatory and respiratory parameters</measure>
    <time_frame>+/- 8 hours</time_frame>
    <description>Systolic and diastolic blood pressure (SBP and DBP), heart rate (HR), and oxygen saturation (SpO2) are evaluate during the study to measure the safety of cardiocirculatory and respiratory parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of regression of motor block by Bromage Scale</measure>
    <time_frame>+/- 9 - 10 hours</time_frame>
    <description>Will be measure the time of recovery of the motor block, the patient have to score note 4 of the Bromage Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The residual analgesic effect</measure>
    <time_frame>+/- 9-10 hours</time_frame>
    <description>Will be evaluated the end of the analgesic effect of the anesthetic solution when the patient asks for pain medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anesthetic failure</measure>
    <time_frame>+/- 45 min</time_frame>
    <description>Evaluation of the anesthetic failure (if occur)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>+/- 8 - 12 hours</time_frame>
    <description>During the study will be evaluate the presence of adverse event due to the anesthetic.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fracture of Lower Limb</condition>
  <arm_group>
    <arm_group_label>bupivacaine S75:R25</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 ml for subarachnoid block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine (S50:R50)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3 ml subarachnoid block</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>single dose of 15mg by a slow injection rate of 1 ml/s</description>
    <arm_group_label>bupivacaine S75:R25</arm_group_label>
    <arm_group_label>bupivacaine (S50:R50)</arm_group_label>
    <other_name>marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA (American Society of Anesthesiologists) I or ASA II

          -  Spinal Anaesthesia for lower limb surgery

          -  Patient Consent

        Exclusion Criteria:

          -  relative or absolute contraindications for spinal anesthesia

          -  history of hypersensitivity to the local anesthetics or components

          -  opioids for anesthetic adjuvant

          -  spinal lesions, peripheral neuropathies or any other neurologic disorders that leads
             to changes of sensitivity

          -  Body mass index = or &gt; 35

          -  lumbar puncture difficulty

          -  ventricular extrasystoles

          -  dementia, others loss of cognitive ability

          -  difficulty in the spine

          -  spinal cord surgery

          -  anaphylactic reactions or Stevens-johnson Syndrome

          -  polytraumatism

          -  alcoholism abuse and use of illicit substance

          -  Changes in the blood test

          -  Others conditions judged by investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ligia Mathias, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Irmandade da Santa Casa de Misericórdia de São Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Sepaco</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade da Santa Casa de Misericórdia de São Paulo</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>March 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2011</study_first_posted>
  <last_update_submitted>March 25, 2014</last_update_submitted>
  <last_update_submitted_qc>March 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

